Furthermore, subgroup analysis indicated that PPP4C is particularly valuable for predicting the prognosis of high-risk DLBCL patients (IPI > 2, ECOG > 2, stage III–IV, and non-GCL). The gene discussed is PPP4C; the disease is diffuse large B-cell lymphoma.